StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
226330.KQ$2030.00-6.02%
Fair $2030.00+0.0%

226330.KQ

SyntekaBio, Inc.

Healthcare / Health Information ServicesKOSDAQ

$2030.00

-130.00 (-6.02%)

Fairly Valued+0.0%Fair Value $2030.00Fund rank 32/100 · Data gapFallback financials|
SA 21/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 23%

FCF escenarios

weak_data · normalized FCF $-16.3B · quality 69.3/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 35/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

21/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -54.7%, below the 5% threshold
Thesis & Journal · 226330.KQLocal privado en este navegador · SyntekaBio, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$37.1B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-54.7%

↓

Gross Margin

100.0%

↑

Debt/Equity

0.22

↑
52-Week Range$2030
$1997$8470

TradingView lightweight chart

226330.KQ price, volumen y niveles de valoración

Último $2,030Periodo -87.8%
Fair value: $2,030

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+141.3%

FCF CAGR

—

FCF margin

-313.0%

FCF / Net income

0.62x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.43B · net income $-17.38B · FCF $-10.73B

2022-FY → 2025-FY

Gross margin

100.0%+0.0% pts

Operating margin

-313.9%+4519.1% pts

Net margin

-506.8%+1340.2% pts

FCF margin

-313.0%+6764.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.43B$3.43B$120.9M$123.4M$244.0M
Net Income$-17.38B$-17.38B$-7.21B$-11.40B$-4.51B
EBITDA$-12.51B$-12.51B$-2.95B$-9.26B$-1.78B
EPS-1115.00-1115.00-790.00-796.00-333.00
Gross Margin100.0%100.0%100.0%100.0%100.0%
Operating Margin-313.9%-313.9%-11805.3%-9947.9%-4833.0%
Net Margin-506.8%-506.8%-5966.9%-9235.9%-1847.0%
Balance Sheet
Debt/Equity0.220.220.290.070.35
Current Ratio1.161.16———
Cash Flow
Free Cash Flow$-10.73B$-10.73B$-16.33B$-17.51B$-17.27B
Returns
ROE-54.7%-54.7%-28.9%-36.5%-14.3%
Valuation
P/B1.001.004.197.173.97
Growth & Yield
Revenue Growth2736.7%2736.7%-2.0%-49.4%—
EPS Growth-41.1%-41.1%0.8%-139.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -73.2%

Total return

-73.2%

Start / end P/E

n/dx → n/dx

EPS bridge

-790.00 → -1115.00

Residual

-73.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-73.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.